Search Result

Results for "

JAK2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (28) Arginase (1) Aurora Kinase (3) Autophagy (11) Bacterial (1) Bcr-Abl (3) Btk (2) CDK (6) COX (2) Deubiquitinase (2) EGFR (3) Endogenous Metabolite (1) ERK (1) FGFR (1) FLT3 (15) GSK-3 (4) HDAC (2) Interleukin Related (4) Isotope-Labeled Compounds (2) JAK (141) LRRK2 (1) MEK (2) Microtubule/Tubulin (1) nAChR (1) NF-κB (1) NO Synthase (1) Orthopoxvirus (1) p38 MAPK (1) Parasite (1) PKC (1) Polo-like Kinase (PLK) (2) PROTACs (4) Reactive Oxygen Species (1) RET (3) Src (1) STAT (17) Syk (6) TGF-β Receptor (2) TNF Receptor (1) Trk Receptor (1) VEGFR (2) Virus Protease (1)
By Research Areas:	Cancer (104) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (54) Metabolic Disease (2)

By Targets:

Apoptosis (28)

Arginase (1)

Aurora Kinase (3)

Autophagy (11)

Bacterial (1)

Bcr-Abl (3)

Btk (2)

CDK (6)

COX (2)

Deubiquitinase (2)

EGFR (3)

Endogenous Metabolite (1)

ERK (1)

FGFR (1)

FLT3 (15)

GSK-3 (4)

HDAC (2)

Interleukin Related (4)

Isotope-Labeled Compounds (2)

JAK (141)

LRRK2 (1)

MEK (2)

Microtubule/Tubulin (1)

nAChR (1)

NF-κB (1)

NO Synthase (1)

Orthopoxvirus (1)

p38 MAPK (1)

Parasite (1)

PKC (1)

Polo-like Kinase (PLK) (2)

PROTACs (4)

Reactive Oxygen Species (1)

RET (3)

Src (1)

STAT (17)

Syk (6)

TGF-β Receptor (2)

TNF Receptor (1)

Trk Receptor (1)

VEGFR (2)

Virus Protease (1)

By Research Areas:

Cancer (104)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (54)

Metabolic Disease (2)

154

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15480

NSC 42834 1 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits* Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-137756

JAK2-IN-6	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-149718

Antitumor agent-123	JAK HDAC	Cancer
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including *JAK2, JAK3, HDAC1* and HDAC6, with IC₅₀ values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models .

HY-100759

JAK2-IN-4

JAK Cancer

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

HY-130247

JAK2/FLT3-IN-1 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-130247A

JAK2/FLT3-IN-1 TFA 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity .

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and *JAK2, respectively. JAK2*/TYK2-IN-2 has anti-inflammatory activity .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-18960

CHZ868

5 Publications Verification

JAK Cancer

CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

CHZ868 5 Publications Verification	JAK	Cancer
CHZ868 is a type II *JAK2* inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of *JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-112391

SD-1029	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation .

HY-131194

JAK2/STAT3-IN-1

Interleukin Related Cancer

JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

JAK2/STAT3-IN-1	Interleukin Related	Cancer
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

HY-115452

G5-7	JAK Apoptosis	Cancer
G5-7, an orally active and allosteric *JAK2* inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr ¹⁰⁶⁸) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .

HY-13775

XL019 4 Publications Verification	JAK Apoptosis	Cancer
XL019 is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-N1405

Cucurbitacin I 5+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-10410

TG101209 4 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-147330

SJ1008030	PROTACs JAK	Cancer
SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 inhibits* MHH–CALL-4 cell growth with an IC₅₀ of 5.4 nM. SJ1008030 can be used for the research of leukemia .

HY-10411

AZ960

JAK Apoptosis Parasite Virus Protease Cancer

AZ960 is a potent and specific inhibitor of the JAK2 kinase with a K_i of 0.45 nM.
HY-107594

Benzene hexabromide

JAK Cancer

Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation.

AZ960	JAK Apoptosis Parasite Virus Protease	Cancer
AZ960 is a potent and specific inhibitor of the *JAK2* kinase with a K_i of 0.45 nM.

Benzene hexabromide	JAK	Cancer
Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of *JAK2* tyrosine kinase autophosphorylation.

HY-N1356

Reticuline	JAK STAT NF-κB Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects .

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-18293

NSC 33994

JAK Autophagy Cancer

NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC₅₀ of 60 nM .

NSC 33994	JAK Autophagy	Cancer
NSC 33994 (G6) is a selective *JAK2* inhibitor, with an IC₅₀ of 60 nM .

HY-146066

α7 nAchR-JAK2-STAT3 agonist 1	nAChR JAK STAT NO Synthase	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-147330A

SJ1008030 TFA	PROTACs JAK	Cancer
SJ1008030 (compound 8) TFA is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 TFA inhibits* MHH–CALL-4 cell growth with an IC₅₀ of 5.4 nM. SJ1008030 TFA can be used for the research of leukemia .

HY-147330B

SJ1008030 formic	PROTACs JAK	Cancer
SJ1008030 (compound 8) formic is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 formic inhibits* MHH–CALL-4 cell growth with an IC₅₀ of 5.4 nM. SJ1008030 formic can be used for the research of leukemia .

HY-109179A

Itacnosertib (hydrocholide)

TP-0184 (hydrocholide)
JAK TGF-β Receptor Cancer

Itacnosertib hydrocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5 .

Itacnosertib (hydrocholide) TP-0184 (hydrocholide)	JAK TGF-β Receptor	Cancer
Itacnosertib hydrocholide is an inhibitor of *JAK2, ACVR1 (ALK2)* and ALK5 .

HY-19631A

Ilginatinib NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631B

Ilginatinib hydrochloride NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-15166B

(E/Z)-Zotiraciclib citrate

(E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
CDK JAK FLT3 Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor .
HY-18301

JAK-IN-35

JAK Cancer

JAK-IN-35 (compound TG46) is a JAK2 inhibitor that canb be used in cancer research .

(E/Z)-Zotiraciclib citrate (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent CDK2, *JAK2, and FLT3* inhibitor .

JAK-IN-35	JAK	Cancer
JAK-IN-35 (compound TG46) is a *JAK2* inhibitor that canb be used in cancer research .

HY-15315A

Baricitinib phosphate 35+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-14722A

NVP-BSK805 dihydrochloride 3 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722

NVP-BSK805 3 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-15343

CEP-33779

2 Publications Verification

JAK Cancer

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC₅₀ of 1.8±0.6 nM.
HY-151256

JAK-2/3-IN-2

JAK Cancer

JAK-2/3-IN-2 (Compound 3h) is a JAK2 and JAK3 inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

CEP-33779 2 Publications Verification	JAK	Cancer
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of *JAK2* with an IC₅₀ of 1.8±0.6 nM.

JAK-2/3-IN-2	JAK	Cancer
JAK-2/3-IN-2 (Compound 3h) is a *JAK2* and JAK3 inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

HY-10409

Fedratinib 30+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10409A

Fedratinib hydrochloride hydrate 30+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-16379

Pacritinib 10+ Cited Publications SB1518	JAK FLT3	Cancer
Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-12000

AG490 Maximum Cited Publications 102 Publications Verification Tyrphostin AG490; Tyrphostin B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-10652

JAK-2/3-IN-1	JAK	Inflammation/Immunology Cancer
JAK-2/3-IN-1 is a potent *JAK-2* and JAK-3 inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms .

HY-149647

HD-2a

Others Inflammation/Immunology

HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells .
HY-145029

SYK/JAK-IN-1

Syk JAK Inflammation/Immunology Cancer

SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively .

HD-2a	Others	Inflammation/Immunology
HA-2a can inhibit the *JAK2/STAT3* pathway via downregulates circDcbld2 expression in RAW264.7 cells .

HY-15166A

(E/Z)-Zotiraciclib hydrochloride 5 Publications Verification (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, *JAK2, and FLT3* inhibitor .

HY-10963

Momelotinib Mesylate CYT387 Mesylate	JAK Autophagy	Cancer
Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-109179

Itacnosertib

TP-0184
JAK TGF-β Receptor Cancer

Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1405

Cucurbitacin I Maximum Cited Publications 10 Publications Verification Elatericin B; JSI-124; NSC-521777	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N1356

Reticuline	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Disease Research Fields Lindera aggregata (Sims) Kosterm.	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects .

HY-N2963

Broussonin E	Structural Classification Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity .

HY-N7452

Coumermycin A1	Structural Classification Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N0678

Icaritin 1 Publications Verification Anhydroicaritin	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[3.

Cat. No.	Product Name	Chemical Structure

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-W062703S

(Rac)-Ruxolitinib-d9

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks